Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for license extension of cobicistat (Tybost)

CHMP recommended license extension as a pharmacokinetic enhancer of atazanavir 300mg or darunavir 800mg once daily in human immunodeficiency virus‑1 infected adults and adolescents, weighing ≥ 35 kg if co‑administered with atazanavir or ≥40 kg if co‑administered with darunavir.


European Medicines Agency